Phase 3 N=19,102 Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
Coronary Artery Disease
Primary: Primary Composite Endpoint — 654; 611 participants — p=0.1969
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
Coronary Artery Disease
Primary: Number of Flow-limiting Coronary Artery Stenosis on CT — 8 Coronary arteries
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Phase 2 N=132 A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
Stable Coronary Heart Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 17; 10; 11; 12 Participants
N/A N=51 PCI Alternative Using Sustained Exercise
Cardiovascular Disease
Primary: Myocardial Perfusion Reserve — 2.76; 2.47; 2.82; 2.52 Ratio
Phase 2 N=20 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
Myocardial Ischemia
Primary: Quantification of Myocardial Blood Volume — 3.63; 1.23 seconds^-1
N/A N=5,179 International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)
Cardiovascular Diseases · Coronary Disease · Coronary Artery Disease
Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…
Phase 3 N=15,871 A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome
Coronary Heart Disease
Primary: Incidence of Cardiovascular Mortality and Morbidity — 0.034050; 0.032759 Event per Patient Years of Followup
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=30 Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: MLD SB Diameter — 08.; 1.0; 2.3; 2.2 mm
N/A N=900 Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Coronary Artery Disease
Primary: Number of Participants With Combination of All Cause Death, Non-fatal Myocardial Infarction (MI), and Hospitalization for Unstable Angina — 34; 28 Participants
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
N/A N=10 Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis
Coronary Artery Disease
Primary: Comparison of CT Derived CACS and Tomosynthesis Scores Correlation
N/A N=120 Multivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
Coronary Disease
Primary: Ability to Detect Stress-induced Myocardial Perfusion Abnormalities by Analysis of MDCT Images Confirmed by Coronary Angiography and/or SPECT. — 78 % accurately detected…
N/A N=306 Data Acquisition for Optimization of Coronary Artery Disease (CAD) Algorithm
Coronary Artery Disease
Primary: The Area Under the Receiver Operating Characteristic Curve of the CAD-score to Separate CAD From Non-CAD Patients. — 73.4 percentage of 100
Phase 4 N=402 Research on Nicorandil Treatment of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina
Stable Angina · Coronary Disease
Primary: Number of Myocardial Ischemia Attacks in 24 Hours — 2.3; 3.8 ischemic attacks per 24 hours — p=<0.0001
Phase 4 N=30 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina
Coronary Artery Disease
Primary: Change in Coronary Artery Flow From Rest to Isometric Handgrip (IHG) Exercise at the End of the Administration of Febuxostat and Placebo — 8.8; 10.7 mL/min — p=0.756
N/A N=58 Disease Management for Coronary Artery Patients
Patient Empowerment · Coronary Artery Disease
Primary: Compliance Questionnaire Scores of the Participants — 22.25; 22.53 score on a scale
Phase 3 N=426 Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI (Based on RPS) - Primary Analysis of Sensitivity Based…
Phase 3 N=15,828 The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial
Atherosclerosis
Primary: Number of Participants With First Occurrence of Any Component of the Composite of Major Adverse Cardiovascular Events (Cardiovascular [CV] Death, Non-fatal Myocardial…
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
N/A N=251 PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
Chest Pain · Cardiovascular Diseases · Angina Pectoris
Primary: Change in Clinicians' Treatment Decision After Age/Sex/Gene Expression Score — 38; 1; 1; 0 number of subjects — p=<0.001
Phase 4 N=697 Evaluation of Integrated Cardiac Imaging in Ischemic Heart Disease
Ischemic Heart Disease
Primary: Diagnosis of IHD at Invasive Coronary Angiography and FFR Measurement — 140 participants
Phase 2 N=48 To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease
Coronary Artery Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 3; 2; 5; 2 Participants
Phase 3 N=478 Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Coronary Artery Disease
Primary: Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded…
Phase 2 N=79 Phase II Study of STA-2 in Patients With Chronic Stable Angina
Chronic Stable Angina
Primary: Change in Total Exercise Time — 450.39; 411.15 seconds — p=0.025
N/A N=116 COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
Phase 3 N=13,026 The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Any Event in the Composite of Major Coronary Events During the Time Period for Follow-up (FU) of Cardiovascular (CV)…
N/A N=150 Stress CT Perfusion in Patients With Chest Pain
Coronary Artery Disease
Primary: Number of Participants With Detected Stress-induced Perfusion Abnormalities by 3D Analysis of MDCT Images — 56 Participants